<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aravantinos, G.</style></author><author><style face="normal" font="default" size="100%">Bafaloukos, D.</style></author><author><style face="normal" font="default" size="100%">Fountzilas, G.</style></author><author><style face="normal" font="default" size="100%">Christodoulou, C.</style></author><author><style face="normal" font="default" size="100%">Papadimitriou, C.</style></author><author><style face="normal" font="default" size="100%">N. Pavlidis</style></author><author><style face="normal" font="default" size="100%">Kalofonos, H.P.</style></author><author><style face="normal" font="default" size="100%">Gogas, H.</style></author><author><style face="normal" font="default" size="100%">Kosmidis, P.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Oncology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Chemotherapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Docetaxel</style></keyword><keyword><style  face="normal" font="default" size="100%">Ovarian cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">Platinum-resistant</style></keyword><keyword><style  face="normal" font="default" size="100%">Vinorelbine</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2003</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2003</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0042200675&amp;doi=10.1093%2fannonc%2fmdg292&amp;partnerID=40&amp;md5=54057ff4731f7e565c14a038c4d92c59</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">1094 - 1099</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Background: This multicenter, prospective phase II study evaluated the safety and efficacy of the combination of docetaxel and vinorelbine in patients with platinum-resistant, paclitaxel-pretreated recurrent ovarian cancer. Patients and methods: Treatment consisted of vinorelbine 25 mg/m2 as a 20-min i.v. infusion (days 1 and 8), and docetaxel 70 mg/m2, as a 1-h i.v. infusion (day 8). Granulocyte colony-stimulating factor support was administered prophylactically on days 12-16. Treatment was repeated every 21 days. Results: Forty-six patients were enrolled. The median number of previous chemotherapeutic regimens was one (range 1-3) with a median treatment-free interval of 4.3 months. Four chemotherapy cycles per patient were administered. Almost 75% of the planned doses for both drugs were given. Forty-one patients are evaluable for response. Three patients (6.5% of all patients; 7.3% of evaluable patients) achieved complete response and eight (17.4% and 19.5%, respectively) a partial response to chemotherapy leading to overall response rates of 23.9% and 26.8%, respectively. Another 34.8% (39.0%) had stable disease. At a median follow-up of 30 months, the median disease-free survival was 13 months, relapse-free survival was 5 months, time to progression was 4.5 months, and overall survival was 9.3 months. Severe toxicities included leukopenia (31%), neutropenia (35%) and febrile neutropenia (20%). Conclusions: The combination of docetaxel/vinorelbine is an effective regimen with manageable toxicity for the treatment of platinum-resistant, paclitaxel-pretreated ovarian cancer.</style></abstract><issue><style face="normal" font="default" size="100%">7</style></issue><notes><style face="normal" font="default" size="100%">Cited By :27Export Date: 21 February 2017</style></notes></record></records></xml>